Cambridge Investment Research Advisors Inc. Trims Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Cambridge Investment Research Advisors Inc. cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 13.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,952 shares of the medical equipment provider’s stock after selling 1,738 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Zimmer Biomet were worth $1,333,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Naples Money Management LLC purchased a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $35,000. Activest Wealth Management raised its stake in shares of Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 275 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Zimmer Biomet by 48.4% during the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after buying an additional 153 shares in the last quarter. Quent Capital LLC raised its stake in shares of Zimmer Biomet by 21.6% during the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after buying an additional 92 shares in the last quarter. Finally, Ancora Advisors LLC raised its stake in shares of Zimmer Biomet by 63.3% during the 3rd quarter. Ancora Advisors LLC now owns 570 shares of the medical equipment provider’s stock worth $64,000 after buying an additional 221 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

ZBH stock opened at $113.37 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $147.50. The stock’s fifty day simple moving average is $120.97 and its 200-day simple moving average is $121.94. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $23.32 billion, a price-to-earnings ratio of 24.54, a price-to-earnings-growth ratio of 2.04 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBHGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter last year, the firm earned $1.89 earnings per share. The business’s revenue was up 3.2% on a year-over-year basis. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. The ex-dividend date is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ZBH shares. Oppenheimer increased their target price on Zimmer Biomet from $150.00 to $155.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Argus upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Tuesday, May 21st. JPMorgan Chase & Co. upped their price target on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. Canaccord Genuity Group restated a “hold” rating and issued a $130.00 price target on shares of Zimmer Biomet in a report on Friday, February 23rd. Finally, StockNews.com cut Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $133.75.

View Our Latest Stock Analysis on ZBH

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

See Also

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.